IL108318A - השיטה לשיפור הפעילות הציטוליטית של תאי דם מונונוקליאריים ע" י אינקובציהשל תאים מונונולארים עם li - 10 - Google Patents
השיטה לשיפור הפעילות הציטוליטית של תאי דם מונונוקליאריים ע" י אינקובציהשל תאים מונונולארים עם li - 10Info
- Publication number
- IL108318A IL108318A IL10831894A IL10831894A IL108318A IL 108318 A IL108318 A IL 108318A IL 10831894 A IL10831894 A IL 10831894A IL 10831894 A IL10831894 A IL 10831894A IL 108318 A IL108318 A IL 108318A
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- peripheral blood
- blood mononuclear
- cells
- mononuclear cells
- Prior art date
Links
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract description 80
- 230000001461 cytolytic effect Effects 0.000 title claims abstract description 56
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 26
- 210000005087 mononuclear cell Anatomy 0.000 title description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 160
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 160
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 81
- 229940076144 interleukin-10 Drugs 0.000 claims description 150
- 102000000588 Interleukin-2 Human genes 0.000 claims description 80
- 230000000694 effects Effects 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 238000011534 incubation Methods 0.000 claims description 25
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims description 15
- 102000052620 human IL10 Human genes 0.000 claims description 14
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 230000020411 cell activation Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 65
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 238000011282 treatment Methods 0.000 description 20
- 239000002609 medium Substances 0.000 description 17
- 230000009089 cytolysis Effects 0.000 description 16
- 108090000978 Interleukin-4 Proteins 0.000 description 14
- 102000004388 Interleukin-4 Human genes 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 239000011651 chromium Substances 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010561 standard procedure Methods 0.000 description 11
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 8
- 229910052804 chromium Inorganic materials 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000001094 effect on targets Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000055229 human IL4 Human genes 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 101150067964 BcRF1 gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000002476 tumorcidal effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011266 cytolytic assay Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 102000055228 human IL5 Human genes 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US377593A | 1993-01-13 | 1993-01-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL108318A0 IL108318A0 (en) | 1994-04-12 |
| IL108318A true IL108318A (he) | 1999-10-28 |
Family
ID=21707537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10831894A IL108318A (he) | 1993-01-13 | 1994-01-12 | השיטה לשיפור הפעילות הציטוליטית של תאי דם מונונוקליאריים ע" י אינקובציהשל תאים מונונולארים עם li - 10 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5871725A (he) |
| EE (1) | EE03170B1 (he) |
| IL (1) | IL108318A (he) |
| MY (1) | MY131599A (he) |
| TW (1) | TW381026B (he) |
| ZA (1) | ZA94212B (he) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1981868A (zh) * | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| WO2002032457A1 (en) * | 2000-07-28 | 2002-04-25 | Chemocentryx, Inc. | Immunologic activities of rhesus cytomegalovirus encoded il-10 and human cytomegalovirus encoded il-10 |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| JP2004529851A (ja) * | 2000-09-12 | 2004-09-30 | ジーントロール バイオセラピューティクス， インコーポレイテッド | ヒトサイトカインの混合物を含む組成物およびその産生方法 |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| CA2536041A1 (en) * | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| IL94878A (en) * | 1989-06-28 | 2003-01-12 | Schering Corp | Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same |
| DE69203443T2 (de) * | 1991-01-16 | 1995-12-07 | Schering Corp | Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. |
| JP3260368B2 (ja) * | 1991-01-16 | 2002-02-25 | シェリング・コーポレーション | インターロイキン−１０による腫瘍性疾患の処置 |
-
1993
- 1993-03-02 TW TW082101518A patent/TW381026B/zh not_active IP Right Cessation
-
1994
- 1994-01-12 MY MYPI94000075A patent/MY131599A/en unknown
- 1994-01-12 ZA ZA94212A patent/ZA94212B/xx unknown
- 1994-01-12 IL IL10831894A patent/IL108318A/he not_active IP Right Cessation
- 1994-11-21 EE EE9400338A patent/EE03170B1/xx unknown
- 1994-11-28 US US08/345,272 patent/US5871725A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5871725A (en) | 1999-02-16 |
| IL108318A0 (en) | 1994-04-12 |
| ZA94212B (en) | 1994-08-26 |
| EE03170B1 (et) | 1999-04-15 |
| TW381026B (en) | 2000-02-01 |
| MY131599A (en) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU707019B2 (en) | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
| Owen-Schaub et al. | Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity | |
| Banks et al. | Interleukin 12: a new clinical player in cytokine therapy. | |
| US5382427A (en) | Use of IL-4 to treat solid tumors | |
| AU710593B2 (en) | Treatment of acute leukemia with interleukin-10 | |
| Yu et al. | IL‐12‐induced tumor regression correlates with in situ activity of IFN‐γ produced by tumor‐infiltrating cells and its secondary induction of anti‐tumor pathways | |
| JP3496937B2 (ja) | コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物 | |
| US5871725A (en) | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
| Lotzová et al. | Function of Interleukin-2-Activated NK Cells in Leukemia Resistance and Treatment | |
| AU2022410872A1 (en) | Dual cytokine fusion proteins comprising multi-subunit cytokines | |
| KR100225322B1 (ko) | 종양괴사인자와 인터루킨-4의 상승작용 조성물 | |
| EP0561927B1 (en) | Pharmaceutical compositions for the treatment of b-cell malignancies | |
| HUT78097A (hu) | IL-10 alkalmazása perifériás vér mononukleáris sejt citolitikus aktivitás stimulálására | |
| Kuramitsu et al. | Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant | |
| CZ205496A3 (cs) | Farmaceutický prostředek k léčení rakoviny, způsob jeho výroby a použití IL-10 k výrobě léčiv k antagonizaci blokády cytotoxiciny vyvolané IL-2 endogenním IL-4 | |
| Faist et al. | Posttraumatic immune suppression as initiator of organ failure | |
| Tanida et al. | Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice | |
| Repke et al. | Therapeutic applications of cytokines for immunostimulation and immunosuppression: An update | |
| JP2000513321A (ja) | インターロイキン１０での急性白血病の処置 | |
| CA2181230A1 (en) | Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
| MXPA98000365A (en) | Treatment of acute leukemia with interleucine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| RH | Patent void |